LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback